Board of Directors

Carl Yankowski

Chairman - Efferent Labs

CEO/Founder/Chief Operating Partner - Westerham Group, LLC

Carl Yankowski parachuted into Palm, Inc. as CEO in December 1999, three months before its $1+ Billion IPO. As CEO he grew the company to a $2 billion sales rate, drove unaided awareness to over 65%, and then restructured it dramatically after the Spring 2001 global economic downturn. Immediately prior to joining Palm, Carl was CEO of The Reebok Brand where he led the worldwide Reebok-brand business, a multibillion enterprise that was acquired by Adidas. During his tenure there, Carl successfully reorganized the company for growth, significantly streamlined operations, and improved profitability.

Dante Pennacchia

Vice Chairman - Efferent Labs

President - Maxualize™

Mr. Pennacchia is a sales and marketing expert with over 25 years experience and successful execution in industries ranging from Consumer Products to Medical Devices and Geographic Information Systems. He has been successful with large, small and start-up businesses. While at ITT C&C Cola, he helped launch game changing consumer beverage products in the U.S., such as Perrier and Capri Sun. As Vice President of Sales and Marketing for a medical device subsidiary of Bausch & Lomb, he helped to grow that business from $26M to $120M in 7 years. After being promoted to VP of Consumer Healthcare Group Sales in 1996 for Bausch & Lomb Consumer Healthcare North America, Dante grew market share to the highest ever achieved at that time.

Bradford Berk, MD, PhD

Director - Efferent Labs

DIRECTOR - ROCHESTER NEURORESTORATIVE INSTITUTE

Dr. Berk is currently Director of the Rochester Neurorestorative Institute. Dr. Berk is also Distinguished Professor of Medicine, Pathology, and Pharmacology & Physiology at the University of Rochester. He received his M.D. and Ph.D. degrees from the University of Rochester. He has served on the faculties of Harvard Medical School, Emory University, and the University of Washington. Dr. Berk was previously CEO of the University of Rochester Medical Center (2006-2015) as well as Chairman of Medicine (1999-2006) and Chief of the Cardiology Unit (1998-2003) at the University of Rochester. In addition he was Director of the Aab Cardiovascular Research Institute. Dr. Berk is a fellow of the American Heart Association and the American College of Cardiology, and a member of the Association of American Physicians.

Efrain Rivera, DM, MBA, JD

Director - Efferent Labs

Senior Vice President, CFO, and Treasurer - Paychex

Efrain Rivera is the Senior Vice President, Chief Financial Officer and Treasurer of Paychex, Inc. Mr. Rivera is a senior financial executive with more than 20 years of experience in finance, accounting and business leadership positions, most recently as Vice President of Finance and Administration for Houghton College since 2009.

Mr. Rivera previously served as Corporate Vice President and Chief Financial Officer for Bausch & Lomb from 2007 to 2009 and, prior to that, as Corporate Vice President and Treasurer from 2004 to 2007. During his twenty years with Bausch & Lomb, Mr. Rivera served in various leadership and financial management roles, including Corporate Vice President and President, Canada and Latin America Division; and Vice President Finance and Controller, Global Vision Care.

Spencer Z. Rosero, MD

Director, Chief Medical Officer

Dr. Rosero serves as the Chief Medical Officer of Efferent Labs, Inc. working with the Scientific Advisors and directing discovery activity.

Dr. Rosero is an Associate Professor of Medicine and Clinical Cardiac Electrophysiology at the University of Rochester Medical Center where he serves as Director of the Hereditary Arrhythmias Clinic. He is a practicing cardiologist who has developed the CytoComm™ and PlexiSense technology through years of work with patients. As a specialist in heart rhythm disorders, Dr. Rosero treats patients using a wide range of therapeutic options including radiofrequency ablation of abnormal rhythms, implantation of electronic medical devices such as pacemakers, defibrilllators (ICD's), and cardiac resynchronization therapy devices.

W.K. (Bill) Rader

Executive Director, President and CEO

Mr. Rader is a serial entrepreneur who sold his first company at age 18. To date he has launched five ventures and orchestrated multiple M&A's. Mr. Rader founded Efferent Labs, Inc. in 2011 with a passion derived from his personal experience. He created Efferent on the shoulders of a company he founded in 1998 and successfully exited in 2015, Raland Technologies (now Raland Compliance Partners). Mr. Rader grew Raland from a one-man startup to an Inc. 500|5000 company with a global footprint and 4 divisions. While leading Raland, he established strategic office locations and provided services to clients including Fortune 500 pharmaceutical, biotech and medical device companies throughout the United States, Europe and Asia. His efforts enabled Raland to become one of the most highly respected and sought after providers within the Life Science industry.

Mr. Rader started his carrer in the engineering sector of the U.S. Navy as a Nuclear Engineering Reactor Controls member of the Submarine Fleet. He holds a Bachelor of Science in Electrical Engineering, is a member of Harvard Business School, Business Innovations in Global Healthcare class of 2015, and a graduate of the University at Buffalo, School of Management. Mr. Rader is a NYBio Fellow, and a member of many industry organizations including ISPE, PDA, IEEE, MedTech, Tech Council/MDBio, and ISA.